Adiponectin (also known as Acrp30, AdipoQ and GBP28) has attracted much attention for its potential therapeutic use in metabolic disorders, as this adipokine exerts pleiotropic metabolic effects on insulin sensitivity, inflammation and angiogenesis, primarily via the adiponectin receptors 1 and 2 (AdipoR1 and AdipoR2), as well as the non-signaling binding protein T-cadherin, regulating glucose and lipid metabolism [19,20]. The gene discussed is ADIPOQ; the disease is metabolic disease.